期刊文献+

CYP2J2的生理功能及其在心血管疾病中的作用 被引量:1

Physiological Functions of CYP2J2 and its Influence on Cardiovascular Diseases
下载PDF
导出
摘要 CYP2J2是一种广泛存在于人体心血管系统、肾脏及肝脏的P450酶。在人体不仅参与外源性物质的代谢,同时还参与花生四烯酸的代谢。由于其分布与功能的特点,在人体心血管系统具有重要调控作用。现就CYP2J2的基因及相应突变,分布以及其生理功能进行简单综述。 As one of Human cytochromes P450,CYP2J2 is abundant in cardiovascular tissue and active in the metabolism of a variety of xenobiotics and arachidonic acid that make it to be one of the most important factor in cardiovascular system.This minireview will provide a general overview of CYP2J2 gene and its polymorphisms,distribution and physiological functions.
出处 《医学综述》 2008年第11期1619-1622,共4页 Medical Recapitulate
关键词 CYP2J2 环氧-二十碳三烯酸 基因多态性 心血管疾病 CYP2J2 Expoxyeicosatrienoic acid Gene polymorphism Cardiovascular diseases
  • 相关文献

参考文献27

  • 1Kikuta Y,Sogawa K,Haniu M,et al. A novel species of cytechrome P-450 (P-450ib) specific for the small intestine of rabbits, cDNA cloning and its expression in COS cells[ J]. J Biol Chem, 1991, 266(27) : 17821-17825.
  • 2Enayetallah AE, French RA, Thibodeau MS, et al. Distribution of soluble epoxide hydrelase and of cytochreme P450 2C8,2C9, and 2J2 in human tissues [ J ]. J Histochem Cytochem,2004,52 (4) : 447 -454.
  • 3Hashizume T, Imaoka S, Mise M,et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes[ J]. J Pharmacol Exp Ther,2002,300( 1 ) :298-304.
  • 4Matsumoto S, Hirama T, Matsubara T,et al. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole[ J]. Drug Metab Dispos,2002,30( 11 ) : 1240-1245.
  • 5Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism [ J]. J Biol Chem,2001,276(39) :36059-36062.
  • 6King LM, Ma J, Srettabunjong S ,et al. Cloning of CYP2J2 gene and identification of functional polymorphisms [ J ]. Mol Pharmacol, 2002,61 (4) :840-852.
  • 7Wang H ,Jiang Y, Liu Y ,et al. CYP2J2 * 7 single nucleotide polymorphism in a Chinese population[ J]. Clin Chim Acta,2006,365 (1/2) :125-128.
  • 8Spiecker M,Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2 [ J ]. Circulation ,2004,110 ( 15 ) :2132-2136.
  • 9Lu T,Ye D,Wang X,et al. Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms[ J]. J Physiol,2006,575 ( Pt 2) :627-644.
  • 10Seubert J, Yang B, Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K^+ channels and p42/p44 MAPK pathway [J]. Circ Res,2004,95(5) :443-445.

同被引文献21

  • 1Seliskar M,Rozman D. Mammalian cytochromes P450 improtance of tissue specificity[J].Biochim Biopys Acta,2007,(03):458-66.
  • 2Paine MF,Hart HL,Ludington SS. The human intestinal cytochrome P450 "pie"[J].Drug Metabolism and Disposition,2006,(05):880-6.
  • 3Alexandrov K,Rojas M,Rolando C. DNA damage by benzo(a)pyrene in human cells is increased by cigarette smoke and decreased by a filter containing rosemary extract,which lowers free radicals[J].Cancer Research,2006,(24):11938-45.
  • 4Wang TL,Li HL,Tiong WY. Genetic contribute to patients pecific warfarin dose for Han Chinese[J].Clinica Chimica Acta,2008,(1/2):76-9.
  • 5Simon C,Stieger B,Kullak-Ublick GA. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition[J].Acta Neurologica Scandinavica,2007,(04):232-42.
  • 6Hayashi M,Matsumoto N,Takenoshita-Nakaya S. Individual metabolic capacity evaluation of cytochrome P450 2C19 by protein and activity in the small intestinal mucosa of Japanese pancreatoduodenectomy patients[J].Biological and Pharmaceutical Bulletin,2011,(01):71-6.
  • 7Hosohata K,Masuda S,Katsura T. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole,but not lansoprazole,in adult living-donor liver transplant patients[J].Drug Metabolism and Disposition,2009,(04):821-6.
  • 8Leon DJ,Susce MT,Murray-Carmichael E. The Amp liChip CYP450 genotyping test:integrating a new clinical tool[J].MOLECULAR DIAGNOSIS & THERAPY,2006,(03):135-51.
  • 9Slanar O,Nobilis M,Kvetina J. CYP2D6 polymorphism,tramadol pharmacokinetics and papillary response[J].European Journal of Clinical Pharmacology,2006,(01):75-6.
  • 10Pedersen RS,Damkier P,Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers[J].European Journal of Clinical Pharmacology,2006,(07):513-21.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部